Correlation between the formation of cleavable complex with topoisomerase I and growth-inhibitory activity for saintopin-type antibiotics

Molecular Pharmacology

Volumn 51, Issue 2, 1997, Pages 269-276

  Fujii, Noboru ^a   Yamashita, Yoshinori ^a   Mizukami, Tamio ^a   Nakano, Hirofumi ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; ANTINEOPLASTIC ANTIBIOTIC; CAMPTOTHECIN; DNA; DNA TOPOISOMERASE; PHOSPHORUS 32; SAINTOPIN; SAINTOPIN E; UCE 1022; UCE 6; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DNA CLEAVAGE; DNA DENATURATION; DNA PROTEIN COMPLEX; DRUG ISOLATION; DRUG STRUCTURE; ENZYME ACTIVITY; GROWTH INHIBITION; HELA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 0031025765     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.51.2.269     Document Type: Article

References (40)

1. Wang, J. C. DNA topoisomerases. Annu. Rev. Biochem. 54: 665-697 (1985).
2. Liu, L. F. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem. 58:351-375 (1989).
3. Muggia, F. M., and H. A. Burris. Clinical development of topoisomerase-interactive drugs. Adv. Pharmacol. 29B:1-31 (1994).
4. Chen, G. L., L. Yang, T. C. Rowe, B. D. Halligan, K. M. Tewey, and L. F. Liu. Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J. Biol. Chem. 259:13560-13566 (1984).
5. Nelson, E. M., K. M. Tewey, and L. F. Liu. Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4′-(9-acridinylamino)-methanesulfon-m-anisidide. Proc. Natl. Acad. Sci. USA 81:1361-1365 (1984).
6. Tewey, K. M., T. C. Rowe, L. Yang, B. D. Halligan, and L. F. Liu. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science (Washington D. C.) 226:466-468 (1984).
7. Capranico, G., F. Zunino, K. W. Kohn, and Y. Pommier. Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: relationship with DNA binding affinity and cytotoxicity. Biochemistry 29:562-569 (1990).
8. Kaneda, N., H. Nagata, T. Furuta, and T. Yokokura. Metabolism and pharmacokinetics of the camptothecin analog CPT-11 in the mouse. Cancer Res. 50:1715-1720 (1990).
9. Wassermann, K., J. Markovits, C. Jaxel, G. Capranico, K. W. Kohn, and Y. Pommier. Effects of morpholinyl doxorubicins, doxorubicin, and actinomycin D on mammalian DNA topoisomerases I and II. Mol. Pharmacol. 38:38-45 (1990).
10. Kingsbury, W. D., J. C. Boehm, D. R. Jakas, K. G. Holden, S. M. Hecht, G. Gallagher, M. J. Caranfa, L. F. Mccabe, L. F. Faucette, R. K. Johnson, and R. P. Hertzberg. Synthesis of water-soluble (aminoalkyl) camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J. Med. Chem. 34:98-107 (1991).
11. Hsiang, Y. H., R. Hertzberg, S. Hecht, and L. F. Liu. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. 260:14873-14878 (1985).
12. Rowe, T. C., G. L. Chen, Y. H. Hsiang, and L. F. Liu. DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II. Cancer Res. 46:2021-2026 (1986).
13. Jaxel, C., K. W. Kohn, M. C. Wani, M. E. Wall, and Y. Pommier. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res. 49:1465-1469 (1989).
14. Yamato, M., Y. Takeuchi, K. Hashigaki, Y. Ikeda, M.-r. Chang, K. Takeuchi, M. Matsushima, T. Tsuruo, T. Tashiro, S. Tsukagoshi, Y. Yamashita, and H. Nakano. Synthesis and antitumor activity of fused tetracyclic quinoline derivatives. 1. J. Med. Chem. 32:1295-1300 (1989).
15. Yamashita, Y., N. Fujii, C. Murakata, T. Ashizawa, M. Okabe, and H. Nakano. Induction of mammalian DNA topoisomerase I mediated DNA cleavage by antitumor indrocarbazole derivatives. Biochemistry 31:12069-12075 (1992).
16. Fujii, N., Y. Yamashita, Y. Saitoh, and H. Nakano. Induction of mammalian DNA topoisomerase I-mediated DNA cleavage and DNA winding by bulgarein. J. Biol. Chem. 268:13160-13165 (1993).
17. Yamashita, Y., S. Kawada, and H. Nakano. Induction of mammalian topoisomerase II dependent DNA cleavage by nonintercalative flavonoids, genistein and orobol. Biochem. Pharmacol. 39:737-744 (1990).
18. Yamashita, Y., S. Kawada, N. Fujii, and H. Nakano. Induction of mammalian topoisomerase II dependent DNA cleavage by antitumor antibiotic streptonigrin. Cancer Res. 50:5841-5844 (1990).
19. Kawada, S., Y. Yamashita, N. Fujii, and H. Nakano. Induction of a heat-stable topoisomerase II-DNA complex by nonintercalative terpenoides, terpentecin and clerocidin. Cancer Res. 51:2922-2925 (1991).
20. Fujii, N., Y. Yamashita, Y. Arima, M. Nagashima, and H. Nakano. Induction of topoisomerase II-mediated DNA cleavage by the plant naphthoquinones plumbagin and shikonin. Antimicrob. Agents Chemother. 36:2589-2594 (1992).
21. Yamashita, Y., S. Kawada, N. Fujii, and H. Nakano. Induction of mammalian DNA topoisomerase I and II mediated DNA cleavage by saintopin, a new antitumor agent from fungus. Biochemistry 30:5838-5845 (1991).
22. Fujii, N., Y. Yamashita, S. Chiba, Y. Uosaki, Y. Saitoh, Y. Tuji, and H. Nakano. UCE6, a new antitumor antibiotic with topoisomerase I mediated DNA cleavage activity, from actinomycetes. J. Antibiotics 46:1173-1174 (1993).
23. Fujii, N., Y. Yamashita, K. Ando, T. Agatsuma, Y. Saitoh, K. Gomi, Y. Nishiie, and H. Nakano. UCE1022, a new antitumor antibiotic with topoisomerase I mediated DNA cleavage activity, from Paecilimyces. J. Antibiotics 47:949-950 (1994).
24. Adachi, Y., E. Kas, and U. K. Laemmli. Preferential, cooperative binding of DNA topoisomerase II to scaffold-associated regions. EMBO J. 8:3997-4006 (1989).
25. Yamashita, Y., Y. Saitoh, K. Ando, K. Takahashi, H. Ohno, and H. Nakano. Saintopin, a new antitumor antibiotic with topoisomerase II dependent DNA cleavage activity, from Paecilimyces. J. Antibiot. 43:1344-1346 (1990).
26. Kirabelli, C. K., H. Bartus, J. O. L. Bartus, R. Johnson, S. M. Mong, C. P. Sung, and S. T. Crooke. Application of a tissue culture microtiter test for the detection of cytotoxic agents from natural products. J. Antibiot. 38: 758-766 (1985).
27. Camilloni, G., F. D. Seta, R. Negri, A. G. Ficca, and E. D. Mauro. Structure of RNA polymerase II promoters: conformational alterations and template properties of circularized Saccharomyces cerevisiae GAL1-GAL10 divergent promoters. EMBO J. 5:763-771 (1986).
28. Pommier, Y., R. E. Schwartz, L. A. Zwelling, and K. W. Kohn. Effects of DNA intercalating agents on topoisomerase II induced DNA strand cleavage in isolated mammalian cell nuclei. Biochemistry 24:6406-6410 (1985).
29. Capranico, G., A. Riva, S. Tinelli, T. Dasdia, and F. Zunino. Markedly reduced level of anthracycline-induced DNA strand breaks in resistant P388 leukemia cells and isolated nuclei. Cancer Res. 47:3752-3756 (1987).
30. Chen, A. Y., C. Yu, B. Gatto, and L. F. Liu. DNA minor groove-binding ligands: a different class of mammalian DNA topoisomerase I inhibitors. Proc. Natl. Acad. Sci. USA 90:8131-8135 (1993).
31. Pommier, Y., A. Orr, K. W. Kohn, and J.-F. Riou. Differential effects of amsacrine and epipodophyllotoxins on topoisomerase II cleavage in the human c-myc protooncogene. Cancer Res. 52:3125-3130 (1987).
32. Leteurtre, F., A. Fujimori, A. Tanizawa, A. Chhabra, A. Mazumder, G. Kohlhagen, H. Nakano, and Y. Pommier. Saintopin, a dual inhibitor of topoisomerases I and II, as a probe for drug-enzyme interactions. J. Biol. Chem. 269:28702-28707 (1994).
33. Capranico, G., P. D. Isabella, S. Tinelli, M. Bigioni, and F. Zunino. Similar sequence specificity of mitoxantrone and VM-26 stimulation of in vitro DNA cleavage by mammalian DNA topoisomerase II. Biochemistry 32: 3038-3046 (1993).
34. Hsiang, Y. H., and L. F. Liu. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 48:1722-1726 (1988).
35. Hsiang, Y. H., and L. F. Liu. Evidence for the reversibility of cellular DNA lesion induced by mammalian topoisomerase II poisons. J. Biol. Chem. 264:9713-9715 (1989).
36. Taniguchi, K., K. Kohno, K. Kawakami, M. Wada, T. Kanematsu, and M. Kuwano. Drug-induced down-regulation of topoisomerase I in human epidermoid cancer cells resistant to saintopin and camptothecin. Cancer Res. 56:2348-2354 (1996).
37. Capranico, G., M. Palumbo, S. Tinelli, and F. Zunino. Unique sequence specificity of topoisomerase II DNA cleavage stimulation and DNA binding mode of streptonigrin. J. Biol. Chem. 269:25004-25009 (1994).
38. Isabella, P. D., G. Capranico, M. Palumbo, C. Sissi, A. P. Krapcho, and F. Zunino. Sequence selectivity of topoisomerase II DNA cleavage stimulated by mitoxantrone derivatives: relationships to drug DNA binding and cellular effects. Mol. Pharmacol. 43:715-721 (1993).
39. Giovanella, B. C., J. S. Stehlin, M. E. Wall, M. C. Wani, A. W. Nicholas, L. F. Liu, R. Silber, and M. Potmesil. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science (Washington D. C.) 246:1046-1048 (1989).
40. Husain, I., J. L. Mohler, H. F. Seigler, and J. M. Besterman. Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res. 54:537-546 (1994).